GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (LTS:0Q4U) » Definitions » Cyclically Adjusted Revenue per Share

Novonesis (Novozymes) B (LTS:0Q4U) Cyclically Adjusted Revenue per Share : kr63.20 (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted revenue per share for the three months ended in Mar. 2025 was kr17.170. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr63.20 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novonesis (Novozymes) B's average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novonesis (Novozymes) B was 9.20% per year. The lowest was 4.40% per year. And the median was 8.10% per year.

As of today (2025-05-28), Novonesis (Novozymes) B's current stock price is kr468.55. Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr63.20. Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio of today is 7.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novonesis (Novozymes) B was 11.43. The lowest was 5.01. And the median was 7.68.


Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.97 48.16 54.03 58.22 62.37

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.22 59.32 59.92 62.37 63.20

Competitive Comparison of Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio falls into.


;
;

Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novonesis (Novozymes) B's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=17.17/120.2000*120.2000
=17.170

Current CPI (Mar. 2025) = 120.2000.

Novonesis (Novozymes) B Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 11.497 100.200 13.792
201506 11.105 100.300 13.308
201509 11.399 100.200 13.674
201512 11.219 99.800 13.512
201603 11.803 100.200 14.159
201606 11.265 100.600 13.460
201609 11.206 100.200 13.443
201612 12.511 100.300 14.993
201703 12.504 101.200 14.852
201706 11.876 101.200 14.106
201709 12.124 101.800 14.315
201712 12.299 101.300 14.594
201803 11.921 101.700 14.090
201806 11.935 102.300 14.023
201809 12.519 102.400 14.695
201812 12.808 102.100 15.079
201903 12.040 102.900 14.064
201906 12.016 102.900 14.036
201909 12.963 102.900 15.142
201912 13.134 102.900 15.342
202003 13.371 103.300 15.559
202006 11.857 103.200 13.810
202009 12.179 103.500 14.144
202012 12.289 103.400 14.286
202103 13.444 104.300 15.493
202106 12.755 105.000 14.601
202109 13.444 105.800 15.274
202112 13.691 106.600 15.438
202203 15.637 109.900 17.103
202206 15.345 113.600 16.237
202209 15.699 116.400 16.212
202212 16.179 115.900 16.779
202303 16.629 117.300 17.040
202306 15.171 116.400 15.666
202309 16.011 117.400 16.393
202312 32.625 116.700 33.603
202403 14.623 118.400 14.845
202406 14.701 118.500 14.912
202412 32.709 118.900 33.067
202503 17.170 120.200 17.170

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novonesis (Novozymes) B  (LTS:0Q4U) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=468.55/63.20
=7.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novonesis (Novozymes) B was 11.43. The lowest was 5.01. And the median was 7.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novonesis (Novozymes) B Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Industry
Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines